PTGS2 and major depressive disorder: A study by Abbasi et al. showed that celecoxib, a drug that selectively targets COX-2, inhibits inflammatory factors in tissues, particularly interleukin (IL)-6 and IL-1, thereby promoting recovery and reducing the risk of relapse in patients with depression (39).